GleamWall
中文EN

AXIM AXIM BIOTECHNOLOGIES, INC.

Pharmaceutical Preparations · OTC · SEC CIK 1514946 · Fiscal year ends 12/31

Financial factors as of 2022-09-30 (2022Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-89.0%
TTM net income YoY-29.0%
TTM EPS YoY282.5%
Revenue 3-yr CAGR-67.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-182,235.4%
Net margin-218,733.8%
FCF margin—
EBITDA margin-142,796.3%

Returns

ROE-10,021.6%
ROA-143.0%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets197.8%
Debt / equity—
Current ratio0.08x
Interest coverage-7.07x

Cash quality & payout

Operating cash flow / net income0.19x
Accruals ratio-116.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31FY20192019-12-31
Income statement
Revenue$39,518$8,875$60,460$0$799,483
Cost of revenue———$0$0
Gross profit———$0$0
R&D expense$125,496$153,697$284,869$426,708$0
SG&A expense$2.24M$4.08M$5.67M$4.51M$3.11M
Operating income-$2.75M-$4.65M-$13.97M-$4.95M-$3.11M
Interest expense$140,000$261,537$140,389$234,754$222,236
Pretax income-$8.06M-$6.24M-$16.02M-$6.29M-$2.97M
Income tax$0$0$0$0$0
Net income-$8.06M-$6.24M-$16.03M-$6.41M-$6.45M
EBITDA-$2.32M-$4.23M-$11.86M-$4.93M-$3.11M
EPS (basic)-0.04-0.040.12-0.06-0.10
EPS (diluted)-0.04-0.040.12-0.06-0.10
Weighted avg. shares (diluted)———110.39M61.95M
Banking
Noninterest expense$0$177,500———
Balance sheet
Cash & equivalents$156,457$47,282$452,963$457,181$511,630
Receivables———$0$315,843
Inventory——$20,089$0$487,814
Current assets$156,457$103,979$636,613$713,104$1.64M
PP&E, net$134,067$93,840$116,810$104,094$2,237
Goodwill——$0$2.46M$0
Intangibles—$3.99M——$50,534
Total assets$4.12M$4.21M$5.32M$11.31M$1.69M
Current liabilities$5.98M$3.39M$2.58M$1.50M$3.40M
Short-term debt$94,829$19,789$180$180$5,000
Long-term debt$137,044————
Total debt$231,873————
Total liabilities$11.78M$9.04M$7.66M$9.75M$8.45M
Shareholders' equity-$7.66M-$4.83M-$2.34M$1.57M-$6.76M
Net debt$75,416————
Shares outstanding245.93M192.44M138.10M125.33M64.85M
Cash flow statement
Operating cash flow-$1.03M-$2.04M-$2.49M-$3.22M-$5.04M
Capital expenditure$0$8,710$40,495$97,324—
Free cash flow-$1.03M-$2.05M-$2.53M-$3.31M—
Investing cash flow$0-$8,710-$50,495$9,980$348,187
Financing cash flow$1.14M$1.65M$2.53M$3.15M$3.40M
Depreciation & amortization$427,019$426,126$2.12M$16,001$3,356
Stock-based compensation$197,727$1.11M$1.14M$2.31M$1.83M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.